title: Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
abstract: OBJECTIVE
  This work aims to explore the safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction (STEMI) undergoing emergency percutaneous coronary intervention (PCI).
  
  
  METHODS
  A total of 104 patients with serious thrombus burden and acute STEMI were randomly divided into treatment (intracoronary tirofiban administration, 56 cases) and control (48 cases) groups. Comparison of coronary blood flow, ST-segment resolution (STR), duration of hospital stay, 30-day major adverse cardiac events (MACE) and complications such as hemorrhage was conducted.
  
  
  RESULTS
  In treatment group, the percentage of thrombolysis in myocardial infarction-3 (TIMI-3) flow in the infarct-related artery (IRA) increased (89.3% to 85.4, p < 0.05), blood flow in the IRA calculated with TIMI frame count method enhanced [(1.68 ± 0.23) ml/s to (1.42 ± 0.31) ml/s, p < 0.05], STR on electrocardiogram (ECG) enlarged [(64.3 ± 7.84)% to (48.6 ± 6.47)%, p < 0.05)] and the prevalence of MACE decreased (10.7% to 18.8%, p < 0.05), all of which were significantly different from those of control group, but no statistical difference in complications was observed between two groups (p > 0.05).
  
  
  CONCLUSIONS
  It was simple, safe and effective to perform intracoronary tirofiban administration in patients with serious thrombus burden and STEMI when undergoing emergency PCI.
authors.affiliation: Department of Cardiology, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China. shiyingxingcn@163.com.
authors.forename: H-L
authors.initials: HL
authors.lastname: Wang
authors.forename: S-Y
authors.initials: SY
authors.lastname: Xing
authors.forename: P-S
authors.initials: PS
authors.lastname: Dong
authors.forename: Y-H
authors.initials: YH
authors.lastname: Han
authors.forename: J-H
authors.initials: JH
authors.lastname: Zhu
authors.forename: L-H
authors.initials: LH
authors.lastname: Lai
authors.forename: J-F
authors.initials: JF
authors.lastname: Zhao
mesh_terms: D003328:Coronary Thrombosis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D005343:Fibrinolytic Agents; D014443:Tyrosine; D000077466:Tirofiban